IceCure Medical Ltd. has announced that the Food and Drug Administration (FDA) has granted its appeal and reopened its De Novo Classification Request for Marketing Authorization of its ProSense cryoablation technology for early-stage breast cancer.
Operator: Good morning and thank you for standing by. Currently, all participants are in a listen-only mode. After management’s discussion there will be a question-and-answer session.
Physician Interest and Adoption of ProSense in the U.S. Builds Momentum as ProSense is Featured at Medical Conferences and Educational Courses ProSense was the.
A presentation during the Radiological Society of North America Scientific Session and Annual Meeting (RSNA 2022) featured IceCure Medical Ltd. and its minimally-invasive cryoablation technology, addressing Increasing interest among breast and interventional radiologists in performing breast tumor cryoablation.